Background Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR
mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access …

Background Afatinib is approved for first-line treatment of patients with epidermal growth
factor receptor mutation-positive (EGFR m+) non-small-cell lung cancer (NSCLC). Here, we …

Background We investigated the clinical characteristics and treatment outcomes of Korean
patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation …

Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …

Background Data from clinical trials and real-world studies show that afatinib is effective in
treating non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal …

Background: Lung cancer is a leading cause of cancer-related death in Germany and
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …

Background Afatinib is indicated for the treatment of EGFR mutation-positive (M+) non-small
cell lung cancer (NSCLC). LUX-Lung trials have demonstrated that afatinib significantly …

Background Afatinib has been shown as a suitable option for the treatment of epidermal
growth factor receptor mutation-positive (EGFR m+) non-small-cell lung cancer (NSCLC) in …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a standard of
care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small …

Afatinib is an ErbB family blocker that is approved for the treatment of epidermal growth
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal …